-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
After successful treatment of hepatocellular carcinoma (HCC), the benefits of direct-acting antiviral drugs (DAA) against hepatitis C virus (HCV) are still controversial.
This study aims to conduct a meta-analysis of individual patient data to assess the risk of liver cancer recurrence after taking DAA in these patients .
Assess the risk of liver cancer recurrence in these patients after taking DAA
Data from 977 patients from 21 HCV-related cirrhosis and HCC studies were included.
HCC recurrence risk/100 person-years
HCC recurrence risk/100 person-yearsThe recurrence rate and death risk of patients in the DAA group were 20/100 person-years (95%CI 13.
The recurrence rate and death risk of patients in the DAA group were 20/100 person-years (95%CI 13.
Among patients with matching propensity scores, there was no significant difference in RR between the exposed group and the non-exposed group (RR=0.
The impact of DAA exposure on the risk of liver cancer recurrence is uncertain
Original source:
Original source:Sapena Victor, Enea Marco, Torres Ferran et al.
Leave a message here